1. Guest, the 'News in Brief' for the week beginning 19th September 2022 is here.
    Dismiss Notice
  2. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Orthostatic intolerance syndromes after hematopoietic cell transplantation, 2021, Vecchié et al

Discussion in ''Conditions related to ME/CFS' news and research' started by ola_cohn, Dec 4, 2021.

  1. ola_cohn

    ola_cohn Established Member (Voting Rights)

    Messages:
    90
    Location:
    Australia
    Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience

    Abstract
    Background

    Hematopoietic cell transplantation (HCT) is an established and potentially curative therapeutic option for hematologic cancers. HCT survivors are at risk of developing long-term complications impacting on morbidity and mortality. Orthostatic hypotension (OH) and postural tachycardia syndrome (POTS) have been anecdotally described after HCT. However, the incidence and clinical characteristics of patients with OH and POTS after HCT has not been well defined.

    Methods
    This retrospective study included 132 patients who had HCT between March 2011 and July 2018 and were referred to Cardio-oncology clinic. Patients were screened for OH and POTS. Using logistic regression analysis we evaluated the association between clinical factors and the incidence of OH and POTS.

    Results
    Median age was 58 (47–63) years, 87 (66%) patients were male, 95 (72%) were Caucasian. OH was diagnosed in 30 (23%) subjects and POTS in 12 (9%) after the HCT. No significant differences in demographic characteristics were found when comparing patients with and without OH or POTS. The two groups did not differ for cardiovascular diseases prevalence nor for the prior use of antihypertensive drugs. Previous radiotherapy and treatment with specific chemotherapy drugs were found to be associated with the incidence of OH or POTS, but none of the factors maintained the significance in the multivariate model. Pharmacological therapy was required in 38 (91%) cases, including a b-adrenergic blocker (n = 24, 57%), midodrine (n = 24, 57%) and fludrocortisone (n = 7, 18%).

    Conclusion
    Orthostatic intolerance syndromes are commonly diagnosed in patients referred to the cardiologist after HCT, involving approximately 1/3 of patients and requiring pharmacological therapy to cope with symptoms in the majority of cases. Risk factors specific to this population are identified but cannot fully explain the incidence of POTS and OH after HCT.

    Open access full text
    https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-021-00126-7
     
    merylg, ahimsa, Yvonne and 6 others like this.
  2. Ash

    Ash Senior Member (Voting Rights)

    Messages:
    297
    Location:
    UK
    ola_cohn, Yvonne and SNT Gatchaman like this.
  3. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    847
    Location:
    New Zealand
    I would also be interested in red cell deformability changes, following HCT. Here is a thread for a recent paper that examined this (in children).
     
    merylg, ola_cohn, Yvonne and 2 others like this.

Share This Page